

PACK-CXL: Defining CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD; J. Bradley Randleman, MD



In medicine, groundbreaking and paradigm-changing treatments often arise from the most simple concepts and constructs, and they often do not require expensive equipment to administer.

THE CONCEPT OF CXL

In 1998, the proof-of-principle for corneal collagen cross-linking (CXL) was born from such a “simple” concept. Combining ultraviolet-A light and a chromophore (vitamin B2, riboflavin), the cornea could be stiffened within a mere half hour and progressive thinning diseases such as keratoconus could be halted.^{1,2} Although still considered a relatively new concept, CXL is now in clinical use worldwide.

Cross-links in the cornea are not a technique, but rather a physiological principle of all connective tissue. This might explain the enormous versatility of the method of CXL: soon after the proof-of-concept in progressive keratoconus, additional indications were established. These include CXL for postoperative ectasia, CXL for bullous keratopathy, CXL in combination with refractive laser procedures (CXL-Plus), and, most interestingly, CXL for infectious keratitis.³⁻¹²

THE NEW TERM: PACK-CXL FOR INFECTIOUS KERATITIS

All attendees present for the 9th Annual International CXL Congress held in Dublin, Ireland, were included in the discussion of terminology and polled to decide the best term to define this new cross-linking application of the cross-linking concept. Although no “perfect” term

surfaced, the best option advanced, and the one promoted for adoption was PACK-CXL: Photo Activated Chromophore for Keratitis. Although the “CXL” suffix is in some ways redundant, the thought (proposed by Cynthia Roberts, PhD) was to link the now ubiquitous CXL abbreviation to the new “PACK” terminology to help unite the literate and facilitate communication on past and future research on the topic.

Photoactivation of a chromophore can act like a disinfectant, reducing the microbial load of a liquid or a tissue. This concept has been in clinical use in transfusion medicine for more than a decade, and may rely on three mechanisms that occur during the light-activation of the chosen chromophore:

1. Intercalation of the chromophore (eg, riboflavin) with the nucleic acids of the pathogen and inhibition of replication.¹³
2. Damage to the pathogen’s cell walls caused by massive amounts of reactive oxygen species.^{14,15}
3. Changes in the tertiary structure of the surrounding stromal collagen fibers, making it difficult for the collagenases to dock to their cleavage sites and exert their function.¹⁶

Clinically, the proof-of-principle of the efficacy of PACK-CXL in treating therapy-resistant microbial keratitis was given in a case series of 5 patients in 2008.¹⁷ Three years later, Makdoui et al.¹⁸ performed a prospective trial with two arms, where one arm comprised patients treated with photoactivated riboflavin only, in the absence of additional antimicrobial treatment. All 16 eyes reported improvement following CXL. The first randomized prospective trial (Geneva–Cairo trial) showed similar promising results,¹⁹ and other smaller and larger case series have been published.²⁰

THE FUTURE OF PACK-CXL: ACCESS TO ALL

Piggybacked on the initial concept of CXL, PACK-CXL has the potential to become a game changer in the treatment of corneal infections. Whereas extended contact lens wear is the major cause of corneal infections

From the Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland (FH); the Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California (FH); and the Department of Ophthalmology, Emory University, Atlanta, Georgia (JBR).

Dr. Hafezi is the co-inventor of the PCT/CH 2012/000090 application. Dr. Randleman has no financial or proprietary interest in the materials presented herein.

Correspondence: Farhad Hafezi, MD, PhD, University of Geneva, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland. E-mail: farhad@hafezi.ch

doi:10.3928/1081597X-20140609-01

in developed countries, minor corneal trauma, combined with significant barriers to access to the health-care system, is causative for corneal ulcers in developing countries, turning corneal infections into a major cause of global blindness.²¹⁻²³

To allow PACK-CXL to make a significant effect globally, the treatment parameters need to address unmet medical needs. These needs include shortening the treatment time, using more efficient chromophores than riboflavin, and providing the technology to every ophthalmologist.

Several research groups are currently working on this exciting new topic. Researchers from Geneva, Switzerland, are currently developing CXL technology that would allow performing a PACK-CXL procedure at the slit lamp, without using expensive operating room infrastructure or additional equipment.

In developed countries, treating a complex corneal infection often may cost thousands of U.S. dollars.²⁴ PACK-CXL provides promises of a less expensive, faster, and more efficient way to kill harmful pathogens that cause corneal infections and later scarring, in a non-pathogen-specific manner and with little cost when compared to conventional pharmaceutical care.

The future might see small portable devices that will allow the comprehensive ophthalmologist to perform a PACK-CXL treatment as soon as the diagnosis of an early infiltrate or a beginning ulcer is made. We look forward to the widespread availability and application of PACK-CXL to shift the paradigm for infectious keratitis management.

REFERENCES

1. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. *Exp Eye Res*. 1998;66:97-103.
2. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol*. 2003;135:620-627.
3. Ehlers N, Hjortdal J, Nielsen K, Sondergaard A. Riboflavin-UVA treatment in the management of edema and nonhealing ulcers of the cornea. *J Refract Surg*. 2009;25:S803-S806.
4. Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. *J Cataract Refract Surg*. 2007;33:2035-2040.
5. Kanellopoulos AJ. Comparison of sequential vs same-day simultaneous collagen cross-linking and topography-guided PRK for treatment of keratoconus. *J Refract Surg*. 2009;25:S812-S818.
6. Kymionis GD, Kontadakis GA, Kounis GA, et al. Simultaneous topography-guided PRK followed by corneal collagen cross-linking for keratoconus. *J Refract Surg*. 2009;25:S807-S811.
7. Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW Jr. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. *J Refract Surg*. 2012;28:706-713.
8. Richoz O, Gatziofufas Z, Francois P, Schrenzel J, Hafezi F. Impact of fluorescein on the antimicrobial efficacy of photoactivated riboflavin in corneal collagen cross-linking. *J Refract Surg*. 2013;29:842-845.
9. Richoz O, Mavrakanas N, Pajic B, Hafezi F. Corneal collagen cross-linking for ectasia after LASIK and photorefractive keratectomy: long-term results. *Ophthalmology*. 2013;120:1354-1359.
10. Salgado JP, Khoramnia R, Lohmann CP, Winkler von Mohrenfels C. Corneal collagen crosslinking in post-LASIK keratectasia. *Br J Ophthalmol*. 2011;95:493-497.
11. Schrier A, Greebel G, Attia H, Trokel S, Smith EF. In vitro antimicrobial efficacy of riboflavin and ultraviolet light on *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Pseudomonas aeruginosa*. *J Refract Surg*. 2009;25:S799-S802.
12. Wollensak G, Aurich H, Wirbelauer C, Pham DT. Potential use of riboflavin/UVA cross-linking in bullous keratopathy. *Ophthalmic Res*. 2009;41:114-117.
13. Naseem I, Ahmad M, Hadi SM. Effect of alkylated and intercalated DNA on the generation of superoxide anion by riboflavin. *Biosci Rep*. 1988;8:485-492.
14. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. *Photochem Photobiol*. 2004;80:15-21.
15. Kumari MV, Yoneda T, Hiramatsu M. Scavenging activity of "beta catechin" on reactive oxygen species generated by photosensitization of riboflavin. *Biochem Mol Biol Int*. 1996;38:1163-1170.
16. Spoerl E, Wollensak G, Seiler T. Increased resistance of cross-linked cornea against enzymatic digestion. *Curr Eye Res*. 2004;29:35-40.
17. Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. *Cornea*. 2008;27:590-594.
18. Makdoui K, Mortensen J, Sorkhabi O, Malmvall BE, Crafoord S. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. *Graefes Arch Clin Exp Ophthalmol*. 2012;250:95-102.
19. Said DG, Elalfy MS, Gatziofufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting [published online ahead of print February 2, 2014]. *Ophthalmology*. doi:10.1016/j.ophtha.2014.01.011
20. Alio JL, Abbouda A, Valle DD, Del Castillo JM, Fernandez JA. Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. *J Ophthalmic Inflamm Infect*. 2013;3:47.
21. Cheng KH, Leung SL, Hoekman HW, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. *Lancet*. 1999;354:181-185.
22. Gonzales CA, Srinivasan M, Whitcher JP, Smolin G. Incidence of corneal ulceration in Madurai district, South India. *Ophthalmic Epidemiol*. 1996;3:159-166.
23. Whitcher JP, Srinivasan M. Corneal ulceration in the developing world: a silent epidemic. *Br J Ophthalmol*. 1997;81:622-623.
24. Keay L, Edwards K, Naduvilath T, et al. Microbial keratitis predisposing factors and morbidity. *Ophthalmology*. 2006;113:109-116.